Tag Archive: #hivr4p

  1. EAVI2020 at HIVR4P

    Leave a Comment

    HIV Research for Prevention (HIVR4P) took place virtually in February and many of EAVI2020’s researchers participated in various capacities. HIVR4P is the only global scientific conference focused exclusively on the challenging and fast-growing field of HIV prevention research and to have so many of our researchers involved is a testament to EAVI2020’s commitment to knowledge exchange with its stakeholders and the scientific community. On the HIVR4P programme committee from EAVI2020 includes Dr Gabriella Scarlatti (OSR, Italy), Prof Damien Purcell (UoM, Australia), Prof Rogier Sanders (AMC, The Netherlands), and Prof Robin Shattock (Imperial UK).

    Below are just some of the presentations, oral abstracts and co-chairing our EAVI2020 researchers carried out at HIVR4P. The conference programme has more details on all sessions.

    EAVI2020 @ HIVR4P


    B and T cells: Old players, new strategies

    Co-chaired by Christian Brander (IrsiCaixa, Barcelona)

    Presentation by Gunilla Karlsson Hedestam (Karolinska Institutet, Sweden) – The maturation of B cell responses

    Early vaccine clinical studies on native-like envelope trimers and germline-targeting immunogens

    Presentation by Katrina Pollock – Native-like trimers based on consensus and mosaic envelope sequences

    Getting the job done: Designing immunogens to induce broadly neutralizing antibodies

    Co-chairs, Tom Hanke (University of Oxford, UK) and Max Crispin (University of Southampton, UK)

    An ambitious and advancing pipeline: T-cell and non-neutralizing antibody-based vaccine strategies

    Presentation by Tom Hanke (University of Oxford, UK) – Refocusing T cell responses with therapeutic vaccination strategies

    First responders

    Presentation by Behazine Combadiere (INSERM, CIMI, France) – Innate immune response signatures (adjuvants)

    Oral Abstracts

    Env and platform designs to improve antibody responses

    Co-chaired by Pauline Maisonnasse (Université Paris-Saclay, France)

    Presentation by Isabella Huettner (King’s College London, UK) – Cross-reactivity between HIV-1 bnAbs and parasite glycans

    Gene-based vaccine approaches

    Co-chaired by Paul McKay (Imperial College London, UK)

    Presentation by Nathifa Moyo (University of Oxford, UK) – Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T cell immunogenicity and breadth

    Presentation by Eric Arts  (Western University, Canada) – A VSV-based HIV-1 vaccine provides protection in macaques against low dose cross-clade SHIVenv_SF162_P3 challenge

    Integrating and optimizing cellular responses

    Presentation by Narcis Saubi (Vall d’Hebron Institut de Recerca, Barcelona) – BCG.HTI2auxo.int priming vaccination enhances the HIV-1 specific T cell immune responses elicited by MVA.HTI

    Building better bNAbs

    Co-chaired by Marit van Gils (AMC, The Netherlands)


    Coming soon to a clinic near you? The antibody infusion pipeline

    Presentation by Marit van Gils (AMC, The Netherlands) – Antibodies against COVID-19

  2. Presentations from EAVI2020 partners at the 2016 Keystone Symposia on HIV Vaccines are available online!

    Leave a Comment

    The Global HIV Vaccine Enterprise in collaboration with Keystone Symposia organized an ePanel discussion and series of SciTalks presentations that brought together key experts in the HIV prevention vaccine field.

    The ePanel and SciTalks addressed a broad range of topics pertinent to state-of-the-art HIV vaccine research. As part of the Global HIV Vaccine Enterprise eAccess Meetings initiative, videos of several presentations recorded onsite at the 2016 Keystone Symposia on HIV Vaccines are available.

    EAVI2020 – present at the 2016 Keystone Symposia on HIV Vaccines

    The Keystone Symposia highlighted cutting-edge scientific developments and challenges in the field in 90-minute sessions that included SciTalk presentations by EAVI2020 Partners:

    Professor Tomas Hanke, from the University of Oxford, presented “A novel conserved-region T-cell mosaic vaccine with very high global coverage of HIV-1 variants is recognized by protective responses in chronic untreated infection” and his presentation is available as a webcast.

    Dr Marit van Gils, from Academisch Medisch Centrum, received the New Investigator Award at HIVR4P and presented “A broadly neutralizing antibody from an elite neutralizer, targets a novel site at the gp120-gp41 interface”. Her presentation is available as a webcast.

    More information

    eAccess Meetings past presentations.
    For more information about EAVI2020, please contact us.

  3. EAVI2020 will be at HIVR4P, Chicago, 17-21 October 2016

    Leave a Comment

    EAVI2020’s partner institutions will be at the HIVR4P Conference in Chicago this week.

    HIV Research for Prevention 2016: AIDS Vaccine, Microbicide, and ARV-based Prevention Science (HIVR4P 2016) will be held 17–21 October 2016 in Chicago, USA.

    HIVR4P is the world’s only scientific meeting dedicated exclusively to the latest research on all forms of biomedical HIV prevention. Through both abstract and non-abstract-driven sessions, HIVR4P supports cross-fertilization among research on HIV vaccines, microbicides, PrEP, treatment as prevention, and other biomedical prevention approaches, while also providing a venue to discuss the research findings, questions, and priorities that are specific to each modality. We expect this cutting-edge, global conference to attract between 1,200 and 1,500 leaders in HIV prevention research, programs, and policy to Chicago.

    More information

    Find more information about the HIVR4P Conference at their website.

    For more information about EAVI2020, please contact us.

    The EAVI2020 team at HIVR4P:

    Pepe Alcami talking behind a lectern

    Pepe Alcami, Instituto de Salud Carlos III, Spain

    Stephen Kent talking behind a lectern on stage

    Stephen Kent, the University of Melbourne, Australia

    Yoann Aldon talking behind a lectern on stage

    Yoann Aldon, Imperial College London, UK

    Anna Janna Behrens on stage at a lectern presenting at a conference

    Anna-Janna Behrens, University of Oxford, UK

    Marit van Gils standing at a HIVR4P desk

    Marit van Gils, Academisch Medisch Centrum, The Netherlands

  4. Marit van Gils selected for the New Investigator Award, HIVR4P conference.

    Leave a Comment

    Marit van Gils, who is part of the Academisch Medisch Centrum‘s team involved in EAVI2020, has been selected as one of eight New Investigator Award recipients of the HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) conference.

    HIVR4P, the first global scientific conference focused exclusively on biomedical HIV prevention research, will be held from 17–21 October in Chicago, Illinois, USA. She will present her work  ‘Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design’ during an oral presentation.


    Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design

    Author(s): Marit van Gils1, Jelle van Schooten1, Christopher Cottrell2, Gabriel Ozorowski2, Robert Morpurgo1, Devin Sok2, Dennis Burton2, John Moore3, Andrew Ward2, Rogier Sanders1

    Institute(s): 1Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2The Scripps Research Institute, San Diego, United States, 3Weill Cornell Medical College, New York, United States

    Background: Broadly neutralizing antibodies (bnAbs) isolated from HIV-1 infected individuals have revealed that the human immune system is capable of eliciting bnAbs that can protect against infection, as confirmed in macaque challenge studies. The BG505 SOSIP trimer has been chosen as the envelope glycoprotein most related to the unmutated common ancestor of the bnAb PG9/PG16 patient. This soluble native-like protein was capable of eliciting neutralizing serum responses against the homologous (Tier-2) virus however, how to broaden the response to target heterologous Tier-2 viruses is still unclear.

    Methods: Immunogen-specific IgG+ B cells from 2 BG505 SOSIP immunized rhesus macaques over time were single-cell sorted to obtain monoclonal antibodies (mAbs). These antibodies were further characterized for their binding and neutralization characteristics.

    Results: We were able to isolate over 40 mAbs from 2 BG505 SOSIP immunized rhesus macaques over time with a diverse set of characteristics. Both neutralizing and non-neutralizing mAbs were isolated with some mAbs only able to bind the trimer and not gp120, and others both trimer and gp120. Epitope mapping and EM revealed several target epitopes, including the V3 and CD4bs for non-neutralizing antibodies and epitopes at sites were the glycan shield was incomplete as some glycans are missing on BG505.

    Conclusions: These results are complementary to mAbs isolated from BG505 immunized rabbits previously, showing additional sites of vulnerability on BG505. The knowledge obtained in this study will provide important information that will help design immunization strategies to broaden the response after vaccination.